William Blair analyst Andy Hsieh has maintained their bullish stance on EXEL stock, giving a Buy rating on February 3.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Andy Hsieh has given his Buy rating due to a combination of factors tied to Exelixis’ solid operating performance and clear growth trajectory. Fourth-quarter product revenue, led by Cabometyx, came in essentially as expected, with favorable gross‑to‑net dynamics more than offsetting temporary inventory effects, and adjusted earnings exceeded prior forecasts, underscoring strong underlying profitability.
Looking ahead, Hsieh highlights 2026 as a potentially pivotal year, with Exelixis’ updated guidance and refined financial model pointing to sustainable earnings power. He also emphasizes the advancing zanzalintinib program, which is moving toward key Phase III readouts and regulatory milestones, positioning the company for an additional revenue driver and supporting an attractive risk‑reward profile at current valuation levels.
In another report released on February 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $52.00 price target.